Axis-Shield gains Sangui CDT (carbohydrate deficient transferrin) line as firms settle:
This article was originally published in Clinica
Sangui Biotech has agreed to stop selling its kits worldwide within 90 days after the company reached agreement with Anglo-Norwegian company Axis-Shield regarding alleged patent infringement on Axis' carbohydrate deficient transferrin (%CDT) assay. In addition, Sangui, of Santa Ana, California, is to sell to Upton, Cambridgeshire-based Axis its CDT business, used for the detection of excessive alcohol consumption, for $100,000.
You may also be interested in...
The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.